参考文献/References:
[1]Gazewood JD,Turner PL.Heart Failure with Preserved Ejection Fraction:Diagnosis and Management[J].Am Fam Physician,2017,96(9):582-588. [2]Parikh KS,Sharma K,Fiuzat M,et al.Heart Failure With Preserved Ejection Fraction Expert Panel Report:Current Controversies and Implications for Clinical Trials[J].JACC Heart Fail,2018,6(8):619-632. [3]宫玉榕,赵红佳,翁苓.2型糖尿病合并射血分数正常心力衰竭患者的超声指标与中医证型相关性研究[J].中国中西医结合影像学杂志,2019,17(1):59-62. [4]何显菁.不同射血分数心力衰竭患者临床特征的对比分析[J].实用心脑肺血管病杂志,2019,27(8):96-99. [5]刘娜娜,郭敏.射血分数保留和降低的慢性心力衰竭临床研究[J].中国心血管病研究,2016,14(4):340-344. [6]Heidenreich PA,Albert NM,Allen LA,et al.Forecasting the impact of heart failure in the United States:a policy statement from the American Heart Association[J].Circ Heart Fail,2013,6(3):606-619. [7]Christofaro DGD,Casonatto J,Vanderlei LCM,et al.Relationship between Resting Heart Rate,Blood Pressure and Pulse Pressure in Adolescents[J].Arq Bras Cardiol,2017,108(5):405-410. [8]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122. [9]王俊文,李艳清,王红.脉压的形成机制与临床意义[J].哈尔滨医科大学学报,2010,44(4):413-416. [10]崔露露.脉压的影响因素及其与靶器官损害的研究进展[J].海南医学,2019,30(10):1336-1340. [11]Lam CSP,Voors AA,De BRA,et al.Heart failure with preserved ejection fraction:from mechainsms to therapies[J].European Heart Journal,2018,39(30):2780-2792. [12]Benetos A.Pulse pressure and carduiovacular risk[J].J Hypertensin,1999,5(1):S21-S22. [13]杨扬,赵瑞平.微量白蛋白尿及脉压差与冠心病的相关性[J].包头医学院学报,2017,33(9):8-11. [14]Lovic D,Narayan P,Pittaras A,et al.Left ventricular hypertrophy in athletes and hypertensive patients[J].J Clin Hypertens(Greenwich),2017,19(4):413-417. [15]Puddey IB,Mori TA,Barden AE,et al.Alcohol and Hyperten sion-New Insights and Lingering Controversies[J].Curr Hypertens Rep,2019,21(10):79. [16]Hadaegh F,Shafiee G,Hatami M,et al.Systolic and diastolic blood pressure,mean arterial pressure and pulse pressure for prediction of cardiovascular events and mortality in a Middle Eastern population[J].Blood Press,2012,21(1):12-18.
相似文献/References:
[1]段淑婷,王义围,王兆鹏.高血压病合并糖调节受损患者血压变异性的相关研究[J].医学信息,2018,31(05):11.[doi:10.3969/j.issn.1006-1959.2018.05.004]
DUAN Shu-ting,WANG Yi-wei,WANG Zhao-peng.Study on Blood Pressure Variability in Patients with Hypertension Complicated with Impaired Glucose Regulation[J].Medical Information,2018,31(01):11.[doi:10.3969/j.issn.1006-1959.2018.05.004]
[2]熊依良.奥美沙坦酯氢氯噻嗪片治疗轻中度原发性高血压的疗效及安全性分析[J].医学信息,2018,31(19):142.[doi:10.3969/j.issn.1006-1959.2018.19.043]
XIONG Yi-liang.Efficacy and Safety of Olmesartan Medoxomil and Hydrochlorothiazide Tablets in the Treatment of Mild to Moderate Essential Hypertension[J].Medical Information,2018,31(01):142.[doi:10.3969/j.issn.1006-1959.2018.19.043]
[3]李信明,刘春梅,任正强,等.供需平衡视角下原发性高血压的病机与防治[J].医学信息,2018,31(19):182.[doi:10.3969/j.issn.1006-1959.2018.19.058]
LI Xin-Ming,LIU Chun-Mei,REN Zheng-Qiang,et al.Pathogenesis and Prevention of Essential Hypertension from the Perspective of Supply and Demand Balance[J].Medical Information,2018,31(01):182.[doi:10.3969/j.issn.1006-1959.2018.19.058]
[4]穆大明.厄贝沙坦氢氯噻嗪与福辛普利治疗原发性高血压的疗效观察[J].医学信息,2019,32(03):151.[doi:10.3969/j.issn.1006-1959.2019.03.049]
MU Da-ming.Efficacy of Irbesartan Hydrochlorothiazide and Fosinopril in the Treatment of Essential Hypertension[J].Medical Information,2019,32(01):151.[doi:10.3969/j.issn.1006-1959.2019.03.049]
[5]潘建鑫.高血压患者血小板/淋巴细胞比值与颈动脉粥样硬化的相关性分析[J].医学信息,2020,33(05):77.[doi:10.3969/j.issn.1006-1959.2020.05.023]
Pan Jianxin.Correlation analysis of platelet/lymphocyte ratio and carotid atherosclerosisin patients with primary hypertension[J].Medical Information,2020,33(01):77.[doi:10.3969/j.issn.1006-1959.2020.05.023]
[6]谢祥红.AngⅡ、ET-1对高血压患者病情发生发展的影响[J].医学信息,2020,33(16):75.[doi:10.3969/j.issn.1006-1959.2020.16.023]
XIE Xiang-hong.Effects of AngⅡ and ET-1 on the Occurrence and Development of Hypertension Patients[J].Medical Information,2020,33(01):75.[doi:10.3969/j.issn.1006-1959.2020.16.023]
[7]魏 炜.奥美沙坦酯和坎地沙坦酯治疗原发性高血压的效果比较[J].医学信息,2021,34(14):160.[doi:10.3969/j.issn.1006-1959.2021.14.045]
WEI Wei.Comparison of the Effects of Olmesartan Medoxomil and Candesartan Cilexetil in the Treatment of Essential Hypertension[J].Medical Information,2021,34(01):160.[doi:10.3969/j.issn.1006-1959.2021.14.045]
[8]郑艳芳,郭军霞,张永春.原发性高血压合并阵发性心房颤动的危险因素分析[J].医学信息,2021,34(22):51.[doi:10.3969/j.issn.1006-1959.2021.22.014]
ZHENG Yan-fang,GUO Jun-xia,ZHANG Yong-chun.Risk Factors Analysis of Essential Hypertension Complicated with Paroxysmal Atrial Fibrillation[J].Medical Information,2021,34(01):51.[doi:10.3969/j.issn.1006-1959.2021.22.014]
[9]谭碧峰,黄友良,凌 莎,等.基于有序Logistic回归模型的H型高血压疗效影响因素研究[J].医学信息,2022,35(05):69.[doi:10.3969/j.issn.1006-1959.2022.05.017]
TAN Bi-feng,HUANG You-liang,LING Sha,et al.Analysis of Influencing Factors on the Efficacy of H-type hypertension Based on Ordinal Logistic Regression Model[J].Medical Information,2022,35(01):69.[doi:10.3969/j.issn.1006-1959.2022.05.017]
[10]张 伟.动态血压监测不同剂型硝苯地平在原发性高血压患者中的治疗效果[J].医学信息,2022,35(10):152.[doi:10.3969/j.issn.1006-1959.2022.10.038]
ZHANG Wei.Effect of Different Dosage Forms of Nifedipine on Ambulatory Blood Pressure Monitoring in Patients with Essential Hypertension[J].Medical Information,2022,35(01):152.[doi:10.3969/j.issn.1006-1959.2022.10.038]